Navigation Links
Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday, August 6, 2008
Date:7/30/2008

erent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2007, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
2. Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates
3. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
4. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
5. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
6. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
7. Alexzas Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference
8. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
9. Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America
10. Alexza Elects Dr. Hal V. Barron to Its Board of Directors
11. 19th Annual Piper Jaffray Health Care Conference to Webcast Alexzas Corporate Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014 ... announced the addition of the  "Global Hormone ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,Hormone ... is a means of replacing hormones that ... body. This type of therapy is usually ...
(Date:8/21/2014)... Rochelle, N.Y. (PRWEB) August 21, 2014 ... is the first private college in the Mid-Hudson Region ... College will now begin accepting applications from qualified “high-technology” ... , “We are very pleased to have been selected ... support Governor Cuomo’s transformative initiative to stimulate economic development ...
(Date:8/21/2014)... OTC Markets Group Inc. ... company, on its approval to list on The ... the best marketplace for established U.S. and global ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO "We ... its growth strategy and achievement of this important ...
(Date:8/21/2014)... Pursuit Solutions ( http://www.pursuit-solutions.com ), a ... for Life Sciences sales and marketing organizations, announced ... Commercial Sales Models” by Peter Robinson, co-founder and ... examines some innovative models used to improve sales ... the pharmaceutical market. Robinson grades the industry on ...
Breaking Biology Technology:Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2
... Cephalon, Inc. (Nasdaq:,CEPH) announced today that the presentation ... JPMorgan Healthcare Conference are now available on the,"Investor Information" ... Tuesday, January 8, 2008, Frank Baldino, Jr.,Ph.D., Chairman and ... beginning at 2:00 p.m. Pacific Time (5 p.m. Eastern ...
... Staff to Continue Record of Investment Success -, ... operationally,independent worldwide biologics unit of AstraZeneca plc (LSE: ... venture capital fund,MedImmune Ventures, will broaden its focus ... by adding the therapeutic areas of,cardiovascular and metabolic ...
... With the SEC Shares Expected to ... HAMBURG, Germany and OXFORD, England, January 7 /PRNewswire-FirstCall/,--, ... Adjustments of,Evotec,s Consolidated Financial Statements With a Positive Net ... September 30 2007, Evotec AG (Frankfurt Stock Exchange: ...
Cached Biology Technology:Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available 2MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas 2MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas 3Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis 2Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis 3Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis 4Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis 5
(Date:8/20/2014)... 20, 2014 George E. Fox, a John and Rebecca ... Houston (UH), was named a fellow in the International Society ... , Fox is one of four members two from ... chosen as fellows in 2014. Fellows are elected every three ... than 500 members from more than 20 countries, the ISSOL ...
(Date:8/20/2014)... Institute (HCI) at the University of Utah have identified ... BCR-ABL, the unregulated enzyme driving the blood cancer chronic ... nearly 6,000 new cases of CML will be diagnosed ... kinase inhibitors (TKIs), target BCR-ABL and are effective at ... control it in a way that allows patients to ...
(Date:8/20/2014)... /CNW/ -  Issue Serious allergic reactions ... life threatening for some children.    What you ... have food allergies and this number may be increasing, especially ... estimated to have food allergies.  The symptoms ... hives to breathing difficulties and loss of consciousness. Symptoms can ...
Breaking Biology News(10 mins):UH professor named fellow by International Astrobiology Society 2Blueprint for next generation of chronic myeloid leukemia treatment 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3
... an avian influenza vaccine with doses as low as ... mixture known as MF59. The research is published in ... available online. , MF 59 is an adjuvant--a ... to a stimulus. For this research, the investigators used ...
... made international headlines in May 2006 when Colin Watson, ... after falling from a 12-meter tree, allegedly while hunting ... of Birds estimates that up to 30 of Britain's ... theory predicts that such exploitation is unlikely to extinguish ...
... C virus turns on human immune defenses upon entering ... manipulating interaction of key cellular proteins, UT Southwestern Medical ... "on/off switch" controls immunity against many viruses, highlighting a ... the researchers report. , In a study available ...
Cached Biology News:A human taste for rarity spells disaster for endangered species 2A human taste for rarity spells disaster for endangered species 3Molecular 'on/off switch' controls immune defenses against viruses 2
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
...
Biology Products: